AbbVie, Inc. (ABBV)
264.49
-0.47
(-0.18%)
USD |
NYSE |
Aug 24, 16:00
264.58
+0.09
(+0.03%)
After-Hours: 20:00
AbbVie Enterprise Value : 532.50B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 532.50B |
| August 20, 2026 | 526.97B |
| August 19, 2026 | 534.29B |
| August 18, 2026 | 521.83B |
| August 17, 2026 | 506.65B |
| August 14, 2026 | 505.11B |
| August 13, 2026 | 507.52B |
| August 12, 2026 | 503.88B |
| August 11, 2026 | 506.23B |
| August 10, 2026 | 502.48B |
| August 07, 2026 | 499.07B |
| August 06, 2026 | 495.24B |
| August 05, 2026 | 499.35B |
| August 04, 2026 | 495.11B |
| August 03, 2026 | 497.41B |
| July 31, 2026 | 507.73B |
| July 30, 2026 | 519.16B |
| July 29, 2026 | 529.57B |
| July 28, 2026 | 529.39B |
| July 27, 2026 | 518.28B |
| July 24, 2026 | 522.61B |
| July 23, 2026 | 518.30B |
| July 22, 2026 | 511.90B |
| July 21, 2026 | 516.85B |
| July 20, 2026 | 512.04B |
| Date | Value |
|---|---|
| July 17, 2026 | 514.00B |
| July 16, 2026 | 513.82B |
| July 15, 2026 | 495.66B |
| July 14, 2026 | 496.84B |
| July 13, 2026 | 502.53B |
| July 10, 2026 | 502.67B |
| July 09, 2026 | 505.91B |
| July 08, 2026 | 510.91B |
| July 07, 2026 | 514.28B |
| July 06, 2026 | 514.48B |
| July 02, 2026 | 525.63B |
| July 01, 2026 | 507.94B |
| June 30, 2026 | 508.97B |
| June 29, 2026 | 512.81B |
| June 26, 2026 | 511.11B |
| June 25, 2026 | 493.07B |
| June 24, 2026 | 478.50B |
| June 23, 2026 | 478.27B |
| June 22, 2026 | 469.88B |
| June 18, 2026 | 445.99B |
| June 17, 2026 | 454.37B |
| June 16, 2026 | 456.56B |
| June 15, 2026 | 455.00B |
| June 12, 2026 | 465.85B |
| June 11, 2026 | 460.62B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Biogen, Inc. | 39.09B |
| Gilead Sciences, Inc. | 202.61B |
| Regeneron Pharmaceuticals, Inc. | 80.94B |
| Amgen, Inc. | 280.82B |
| REGENXBIO, Inc. | 725.36M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.604B |
| Revenue (Quarterly) | 16.99B |
| Total Expenses (Quarterly) | 13.39B |
| EPS Diluted (Quarterly) | 2.033 |
| Gross Profit Margin (Quarterly) | 74.71% |
| Profit Margin (Quarterly) | 21.21% |
| Earnings Yield | 1.34% |
| Operating Earnings Yield | 4.69% |
| Normalized Earnings Yield | 3.044 |